Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GLIKSON, M.
Right arrow Articles by REVAH, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by GLIKSON, M.
Right arrow Articles by REVAH, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1991 Oxford University Press

other

The Influence of Pyridostigmine Administration on Human Neuromuscular Functions—Studies in Healthy Human Subjects

M. GLIKSON, A. ACHIRON*, Z. RAM, A. AYALON{dagger}, A. KARNI, I. SAROVA-PINCHAS{ddagger}, J. GLOVINSKI and M. REVAH

Israel Defense Forces Medical Corps Israel *Department of Neurology, Beilinson Medical Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University Tel Aviv Israel {dagger}Zmman College of Physical Education, Wingate Institute; Tel Aviv University Tel Aviv Israel {ddagger}Departmenl of Neurology, E. Wolfson Medical Center, Holon and Sackler Faculty of Medicine,Tel Aviv University Tel Aviv Israel

Received March 12, 1990; accepted August 21, 1990

Pyridostigmine has a protective effect against organophosphate poisoning when given in a dosage of 30 mg three times daily causing 20–40% cholinesterase inhibition. To test its safety in the human neuromuscular system, a double-blind study on 35 subjects divided into two matched groups was performed. One group was treated with pyridostigmine in a dose of 30 mg three times daily and the other group was treated similarly with placebo, both for a 10-day period. The resultant average cholinesterase inhibition in the treatment group was 23%. Muscle strength and endurance were tested before, during (on the 8th day), and after treatment. Electrodiagnostic studies, including nerve conduction, electromyography, and response to repetitive stimulation, were carried out on four subjects of the treatment group and on two subjects of the placebo group, both before and during treatment (eighth day). Isometric handgrip strength, isokinetic elbow flexor, and extensor strength did not differ between groups as a result of the treatment. Knee flexor and extensor isokinetic strength showed a small (but statistically significant) trend to improve more during placebo treatment, whereas knee extensor endurance decreased slightly in the placebo group. Both these effects are probably due to large fluctuations in performance of the placebo group, whereas the treatment group performance was quite constant. They probably do not represent any adverse effect of pyridostigmine. No electrophysiological changes were found in any of the subjects during treatment. We conclude that pyridostigmine does not cause any significant neuromuscular effect in healthy subjects when taken in a dosage of 90 mg daily for 8 days, causing 20–30% inhibition of Cholinesterase.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.